Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VEGF superagonist
- Development stage
- Preclinical
- Lead developer
- Trophogen
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Parenteral
01
Overview
VEGF superagonist is a recombinant protein analog developed by Trophogen, designed to act as a high-potency activator of the Vascular Endothelial Growth Factor (VEGF) receptor. While most VEGF-targeted therapies in oncology are inhibitors designed to block angiogenesis, this superagonist is being developed for the imaging and treatment of thyroid cancer and other solid tumors. The program includes both human and veterinary applications, with the latter specifically targeting cancers in dogs. By hyper-activating the VEGF receptor, the agent is intended to facilitate specific imaging or therapeutic strategies. It is currently in the preclinical stage of development.
- Other names
- VEGF superagonist (human)VEGF superagonist (animal)
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on VEGF superagonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VEGF superagonist.